Patterns of HIV Treatment Preferences Among People With Diverse Demographic, Social, and Behavioral Characteristics Who Are Living With HIV in the United States

New dosage form and frequency options may improve HIV treatment outcomes and reduce disparities in access and use.

People with HIV in the United States completed a demographic and discrete choice experiment survey of preference for 13 hypothetical HIV treatment options: daily and weekly oral tablets; 1-, 3-, or 6-monthly injections by self or a health care provider (HCP); yearly implant; or combinations. Best-Worst Scaling and a latent class model were used to analyze overall preference choices and for groups of individuals with similar patterns of preferences; the model also predicted uptake of products.

Among the diverse 829 respondents, weekly oral tablets and 6-monthly injections by an HCP were significantly more favored than daily oral tablets. Convenience of the treatment and being tired of taking pills were the top drivers of preference responses. Latent class analysis identified 4 groups of respondents with distinct preference patterns; approximately two-thirds belonged to groups strongly preferring products other than daily oral tablets. The modelled uptake of a weekly pill, yearly implant, 6-monthly HCP injection, oral daily pill, and 3-monthly HCP injections were 24%, 24%, 24%, 18%, and 11%, respectively.

Patterns of HIV medication preference can inform development of new forms of HIV therapy products because the majority of patients do not prefer the currently most available treatment option of daily oral tablets. Looking beyond population-level preferences and into similar groups of people with HIV increases the ability to develop patient-centered products to fill gaps in care and increase treatment effectiveness.